Tocilizumab in the treatment of the adult-onset Still's disease: Current clinical evidence

Clinical Rheumatology

Volumn 32, Issue 1, 2013, Pages 141-147

  De Boysson, Hubert ^a,b   Février, Jérome ^a   Nicolle, Amélie ^a   Auzary, Christophe ^a   Geffray, Loïk ^a  

^a Centre Hospitalier Robert Bisson   (France)

^b CHU CÔTE DE NACRE   (France)

Author keywords

Adult onset Still's disease; Macrophage activation syndrome; Tocilizumab

Indexed keywords

IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB;

ADULT; ADULT ONSET STILL DISEASE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; LABORATORY TEST; MACROPHAGE ACTIVATION SYNDROME; PRIORITY JOURNAL; RASH; RELAPSE; REVIEW; SIDE EFFECT; TREATMENT DURATION; VIRUS REACTIVATION; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HUMANS; MIDDLE AGED; REMISSION INDUCTION; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873412315     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2105-2     Document Type: Review

References (33)

1. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H (1992) Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424-430
2. Fautrel B (2008) Adult-onset Still disease. Best Pract Res Clin Rheumatol 22(5):773-792. doi:10.1016/j.berh.2008.08.006
3. Cunha ML, Wagner J, Osawa A, Scheinberg M (2010) The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease. Rheumatology (Oxford) 49 (5):1014-1016
4. De Bandt M, Saint-Marcoux B (2009) Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68:153-154
5. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K (2002) Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 46:3388-3389
6. Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Takasugi K (2011) Successful tocilizumab treatment in a patient with adultonset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol Jpn Rheum Assoc 21 (2):215-218. doi:10.1007/s10165-010-0365-8
7. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A (2011) Benefit and a possible risk of tocilizumab therapy for adultonset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol Jpn Rheum Assoc 21(1):92-96. doi:10.1007/s10165-010-0348-9
8. Lopez Buitrago R, Estrada Dorronsoro S, Cervera Segura R, Espinosa Garriga G (2012) Tocilizumab effectiveness in adult Still's disease. Med Clin (Barc) 138(1):42-43
9. Matsumoto K, Nagashima T, Takatori S, Kawahara Y, Yagi M, Iwamoto M, Okazaki H, Minota S (2009) Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 28(4):485-487. doi:10.1007/s10067-009-1097-z
10. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N (2009) A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol Jpn Rheum Assoc 19:69-72
11. Naniwa T, Ito R, Watanabe M, Hayami Y, Maeda S, Sasaki K, Iwagaitsu S (2010) Case report: successful use of short-term addon tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol. doi:10.1007/s10067-010-1562-8
12. Perdan-Pirkmajer K, Praprotnik S, TomsicM(2010) A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 29:1465-1467
13. Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, Kahn JE, Lequen L, Longy-Boursier M, Perdriger A, Schaeverbeke T, Toussirot E, Sibilia J (2011) Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken) 63 (1):155-159. doi:10.1002/acr.20319
14. Rech J, Ronneberger M, Englbrecht M, Finzel S, Katzenbeisser J, Manger K, Manger B, Schett G (2011) Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 70(2):390-392. doi:10.1136/ard.2010.129403
15. Rkiouak A, Ennibi K, Zinebi A, Akhouad Y, Reggad A, Rabhi M, Chaari J (2012) Adult refractory Still disease with atypical articular manifestations: efficacity of interleukin-6 antagonists (tocilizumab). Ann Pharm Fr 70(3):163-168. doi:10.1016/j.pharma.2012.03.001
16. Sabnis GR, Gokhale YA, Kulkarni UP (2011) Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis-efficacy of interleukin-6 blockade and review of the literature. Semin Arthritis Rheum 40(4):365-368. doi:10.1016/j.semarthrit.2010.05.003
17. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, Amano K (2012) Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol 31(3):569-574. doi:10.1007/s10067-011-1917-9
18. Sekkach Y, Elqatni M, Khattabi AE, Fatihi J, Hammi S, Badaoui M, Elomri N, Mekouar F, Amezyane T, Abouzahir A, Ghafir D (2011) Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease. Press Med 40(7-8):333-337. doi:10.1016/j.lpm.2011.03.012
19. Sumida K, Ubara Y, Hoshino J, Suwabe T, Hiramatsu R, Hasegawa E, Hayami N, Yamanouchi M, Sawa N, Takemoto F, Takaichi K (2010) Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 29(10):1191-1194. doi:10.1007/s10067-010-1418-2
20. Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C (2011) Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 31(12):1653-1656. doi:10.1007/s00296-010-1631-y
21. Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T (2011) Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adultonset Still's disease. Intern Med 50(16):1757-1760
22. Yoshimura M, Makiyama J, Koga T, Miyashita T, Izumi Y, Torigoshi T, Motokawa S, Eguchi K, Migita K (2010) Successful treatment with tocilizumab in a patient with refractory adultonset Still's disease (AOSD). Clin Exp Rheumatol 28(1):141-142
23. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52(6):1794-1803. doi:10.1002/art.21061
24. Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31 (11):2189-2198
25. Scheinberg MA, Chapira E, Fernandes ML, Hubscher O (1996) Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 14(6):653-655
26. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112 (10):3959-3964. doi:10.1182/blood-2008-05-155846
27. Yokota S, Imagawa T, MoriM, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006. doi:10.1016/S0140-6736(08)60454-7
28. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162-1167. doi:10.1136/ard.2006.068064
29. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC (2006) Reactive haemophagocytic syndrome in adultonset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis 65(12):1596-1601. doi:10.1136/ard.2005.046904
30. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, YachieA(2012) Tocilizumabmasks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 58(2):287-294. doi:10.1016/j.cyto.2012.02.006
31. Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, Azuma N, Katada Y, Sawaki J, Tsutsui H, Matsui K, Maeda A, Nakanishi K (2004) Adult Still's disease reflects a Th2 rather than a Th1 cytokine profile. Clin Immunol 112(1):120-125. doi:10.1016/j.clim.2004.03.023
32. Mima T, Nishimoto N (2009) Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 21(3):224-230. doi:10.1097/BOR.0b013e3283295fec
33. Ostrowski RA, Tehrani R, Kadanoff R (2011) Refractory adultonset still disease successfully treated with abatacept. J Clin Rheumatol: Pract Rep Rheum Musculoskelet Dis 17(6):315-317. doi:10.1097/RHU.0b013e31822c53ad